A global leader in precision medicine, our mission is to create new opportunities for earlier disease
protection through genetic disorder testing, beginning with ophthalmology.
Combining traditional scientific methods with AI, Avellino is able to power more accurate and timely
solutions for modern eyecare practices. This is just the start.
Avellino empowers eyecare professionals and their patients with appropriate and timely information
for early risk detection and diagnosis to achieve the best possible outcomes.
Avellino is building upon the success of its proprietary Universal test, the world's first DNA diagnostic tool
confirming the presence of genetic indicators positively associated with corneal diseases, and applying
those discoveries beyond eye care. This provides life-changing information for patient treatment
decisions and follow-up care.
Avellino’s full-service model ensures that genetic data is the basis for development and a continual
confirmation tool for the success of all therapies.
We are also pioneering CRISPR gene editing to manage and potentially cure
inherited diseases, such as lattice corneal dystrophy, granular corneal dystrophy, and Reis-Bucklers
dystrophy. CRISPR may make it possible to eventually eradicate genetic diseases once and for all.
In late 2019/early 2020, the AvaGen test will be available for clinicians and patients as the first
combination genetic diagnostic tool for determining the risk of developing keratoconus and the presence of
The predictive power of AvaGen will pinpoint, with next-generation accuracy, a predisposition to these
diseases, years before the symptoms may be detectable by the most sensitive clinical tools.
Headquartered in Silicon Valley, California, Avellino has additional operations in Korea, Japan, China,
and the United Kingdom.
Our work is singularly focused on advancing the application of genetic technologies
to deliver on
the promise of precision medicine for improved healthcare outcomes for all.”
Chairman, Founder, President, Avellino
We’re excited to bring our operational model of genetic data, genetic diagnostics,
gene therapies into the practice so more and more physicians can actually utilize this in defining
these for their patients. We believe the future is precision medicine and we will continue to work
hard to make sure it is available to as many as possible.”
Chief Sales and Marketing Officer, Avellino
It’s an extremely interesting time. We are now able to identify what is actually
patients and proactively identify and help ensure patient safety, reliability, and confidence.
Patients are demanding more out of physicians every day. I look forward to the evolution over the
next several years and how Avellino is leading the way in genetic testing.”
Avellino Board of Directors